Abstract: Described is a stable radiopharmaceutical composition in which the decrease in the radiochemical purity over time is suppressed even in the case where the radioactivity concentration is high immediately after production. The stabilized radiopharmaceutical composition includes a polypeptide labeled with a radionuclide and having a group selected from the group consisting of a thioether group and a thiol group, as an active ingredient, a solubilizing agent having an ethylene glycol group, a solvent including water, and a stabilizer selected from the group consisting of a sulfur-containing amino acid or a salt thereof, a sulfur-containing amino acid derivative or a salt thereof, and a polysaccharide.

Abstract: A process and a polyurethane material for molding a semi-rigid integral skin foam which comprising an integral skin having a low degree of foaming and a core having a high degree of foaming. The process includes evacuating a mold cavity to reduce the pressure thereof below atmospheric pressure; injecting into the evacuated mold cavity a polyurethane material; and foaming the material to fill the cavity. The polyurethane material contains a polyol component and an isocyanate component with, at most, 5 parts by weight of a solvent for 100 parts by weight of the polyol component, in the absence of freon.

Abstract: A process for molding a semi-rigid integral skin foam which comprising an integral skin having a low degree of foaming and a core having a high degree of foaming. The process includes evacuating a mold cavity to a pressure of from above 50 to 700 Torr; injecting, into the evacuated mold cavity, a polyurethane material which contains a polyol component and an isocyanate component with air bubbles introduced therein by air loading, in the substantial absence of a foaming agent; and foaming the material to fill the cavity.